SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-025489
Filing Date
2021-04-05
Accepted
2021-04-05 19:30:27
Documents
2
Period of Report
2021-04-02

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1630
2 POA DOCUMENT poa.txt EX-24.3_978003 3594
  Complete submission text file 0001209191-21-025489.txt   6661
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON NJ 08540
Business Address
Eliades George Christopher (Reporting) CIK: 0001855251 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39112 | Film No.: 21807493